WALTHAM, Mass. ,
Sept. 15, 2020 /PRNewswire/
-- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader
in serving science, today announced it is investing more than
$140 million to further expand its
laboratory plastics consumables production to support significant
global demand for COVID-19 testing, as well as development and
manufacturing of therapies and vaccines.
"Early in the pandemic, we quickly joined forces with
governments, public health agencies and industry to increase
capacity across our laboratory plastics production facilities and
address the growing COVID-19 threat," said Fred Lowery, senior
vice president and president of Life Sciences Solutions and
Laboratory Products at Thermo Fisher Scientific. "However, demand
quickly exceeded those early expansion projects, so we began a
series of additional expansions to meet the growing needs of our
customers. These investments, along with many others across the
company, will ensure that our customers have the supplies they need
to continue meeting the unprecedented demands of the COVID-19
response."
The rapid increase in production related to COVID-19 testing,
and development and manufacturing of therapies and vaccines, has
created historic demand for laboratory plastics, including pipette
and automation tips, storage tubes and plates, transfer pipettes,
and packaging vials and bottles. To support these needs, Thermo
Fisher is creating more than 1,000 jobs across manufacturing sites
globally, increasing automation capabilities and optimizing
warehouse and sterilization capacity to improve supply chain
agility.
Among the Thermo Fisher sites currently being expanded are
Rochester, N.Y.; Petaluma, Calif.; Monterrey and Tijuana, Mexico; and Joensuu, Finland.
Thermo Fisher offers an extensive range of laboratory plastics,
including Thermo Scientific Nalgene and Nunc plasticware and the
Thermo Scientific Manual and Electronic Pipetting Systems. From
bottles, beakers, funnels and tubes to pipettes, tips and
diagnostic plates, Thermo Fisher consumables support critical
COVID-19 work globally and include sample collection vials for
diagnostic test kits, pipettes for test processing, lab essentials
for research into therapies and vaccines, lab plastics to support
clinical and epidemiological studies, and materials for vaccine
production and biobanking.
For more information about the Thermo Scientific range of
laboratory plastic consumables, please
visit www.thermofisher.com/backtothelab.
About Thermo Fisher Scientific
Thermo Fisher
Scientific Inc. is the world leader in serving science, with annual
revenue exceeding $25 billion. Our
Mission is to enable our customers to make the world healthier,
cleaner and safer. Whether our customers are accelerating life
sciences research, solving complex analytical challenges, improving
patient diagnostics and therapies or increasing productivity in
their laboratories, we are here to support them. Our global team of
more than 75,000 colleagues delivers an unrivaled combination of
innovative technologies, purchasing convenience and pharmaceutical
services through our industry-leading brands, including Thermo
Scientific, Applied Biosystems, Invitrogen, Fisher Scientific,
Unity Lab Services and Patheon. For more information, please visit
www.thermofisher.com.
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-further-expands-laboratory-plastics-production-to-support-covid-19-testing-therapies-and-vaccines-301130847.html
SOURCE Thermo Fisher Scientific